JBR Clinical Research Sprain & Strain Study

Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)

Feb 16, 2023 | Blog, Case Study

CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial, published in The Lancet.

Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial

Dec 30, 2022 | Blog, Case Study, CenExel, CenExel CNS, Clinical Trial

Primer on the Autonomic Nervous System – 4th Edition

Dec 28, 2022 | Blog, CenExel CNS, Psychiatry

This book provides a concise and accessible overview of autonomic neuroscience for students, scientists, and clinicians.

Update on COVID-19

To: Our Sponsors, CROs, Patients, and Employees

At CenExel Clinical Research, our top priorities are the safety and health of our patients and employees. For our Centers of Excellence to provide the highest quality of clinical research, we established and maintain a COVID-19 Task Force with representatives from every Center. The Task Force is charged with continuous monitoring of the pandemic and providing guidance and communication.

Our clinical operations continue, and we have implemented the following additional safety measures:

Enhanced screening of everyone entering any of our facilities before they are admitted into our offices or clinical areas
Reinforced internal communication regarding the COVID-19 situation, CDC and SHRM recommendations, digital team meetings, and the importance of using sick leave for anyone who has signs, symptoms, or recent exposure to someone with suspected or diagnosed COVID-19
Additional cleaning and disinfecting materials provided through our clinic and office areas
Cross-training and preparations for contingency plans if key staff need to stay home

We will continue to monitor the current situation, coordinate with the proper authorities, and update our policies and procedures as needed to ensure the safety of our patients and employees.